rs13420827 — DNMT3A
3' UTR variant in the de novo DNA methyltransferase DNMT3A, associated with altered DNMT3A expression, modestly reduced gastric cancer risk in some populations, and interaction effects with folate intake and H. pylori infection on cancer and cardiovascular risk
Details
- Gene
- DNMT3A
- Chromosome
- 2
- Risk allele
- G
- Clinical
- Uncertain
- Evidence
- Emerging
Population Frequency
Category
Methylation & DetoxSee your personal result for DNMT3A
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
DNMT3A rs13420827 — A Regulatory Switch in the Epigenome's Master Writer
Your DNA sequence is only half the story. The other half is the epigenome —
the system of chemical tags that determines which genes get expressed and when.
DNMT3A (DNA methyltransferase 3 alpha) is one of the principal enzymes that
writes these tags, adding methyl groups11 methyl groups
A methyl group (–CH₃) attached to
the cytosine base creates 5-methylcytosine, which silences gene expression
without altering the underlying DNA sequence
to cytosines throughout the genome. rs13420827 lies in the 3' untranslated
region (3' UTR) of DNMT3A — a stretch of mRNA that controls how efficiently
the cell produces DNMT3A protein — and may subtly tune the global output of
this critical methylation enzyme.
The Mechanism
rs13420827 is located at chromosome 2, position 25,231,098 (GRCh38), in the
3' UTR of DNMT3A. The plus-strand reference allele is C; the alternate allele
is G. DNMT3A is transcribed from the minus strand, so in the mRNA context the
variant appears in the 3' untranslated tail. The 3' UTR22 3' UTR
The region after the
stop codon in an mRNA; it contains binding sites for microRNAs and RNA-binding
proteins that control transcript stability and translation efficiency is a
hotspot for post-transcriptional regulation: binding sites for microRNAs and
RNA-binding proteins that stabilize or destabilize the transcript. A C-to-G
change in this region can create or destroy such binding sites, subtly altering
how much DNMT3A protein each cell produces. No functional luciferase or
reporter assay has been published for rs13420827 specifically — the mechanism
is inferred from the variant's location and its epidemiological associations.
DNMT3A is responsible for de novo methylation: placing new methyl marks on previously unmethylated cytosines, particularly during early development, hematopoiesis, and adult tissue maintenance. It draws its methyl groups from SAM (S-adenosylmethionine), the universal methyl donor synthesized from methionine by the one-carbon cycle. Any variant that alters DNMT3A expression therefore shifts the enzymatic demand for SAM and interacts with the adequacy of the folate-B12 methylation pathway.
The Evidence
The clearest functional signal comes from a one-carbon pathway study in ovarian
cancer33 one-carbon pathway study in ovarian
cancer
Kelemen LE et al. Genetic variation in the one-carbon transfer pathway
and ovarian cancer risk. Cancer Research, 2008
in 829 cases and 941 controls. Among women who took multivitamin supplements,
the G allele was associated with reduced ovarian cancer risk (OR 0.8, 95% CI
0.6–1.0; p interaction=0.006). The interaction specifically with multivitamin
use — and not in non-users — suggests the variant's effect is conditioned on
the availability of folate and B-vitamins that sustain DNMT3A's substrate pool.
This is consistent with a model in which the G allele modestly reduces DNMT3A
output, and adequate methyl-donor supply partially compensates.
In gastric cancer, findings have been mixed. A case-control study in Southern
China44 case-control study in Southern
China
Yang XX et al. Risk-association of DNA methyltransferases polymorphisms
with gastric cancer in the Southern Chinese population. Int J Mol Sci, 2012
found rs13420827 associated with reduced gastric cancer risk under the
overdominant model (OR 0.66, 95% CI 0.45–0.97, p=0.034) in 242 cases and 294
controls. A separate Chinese case-control study55 case-control study
Zhou J et al. Association of
five genetic variations in DNMT1 and DNMT3A with gastric cancer in a Chinese
population. Future Oncology, 2018
found the CG/GG genotypes associated with reduced cancer risk in individuals
aged ≤60, and with reduced risk of poorly differentiated or advanced-stage
tumors. However, a meta-analysis covering 13 studies66 meta-analysis covering 13 studies
Li H et al. DNMT1,
DNMT3A and DNMT3B Polymorphisms Associated With Gastric Cancer Risk.
EBioMedicine, 2016 (3,959 cases /
5,992 controls) found rs13420827 not significantly associated with overall
gastric cancer risk. The gastric cancer evidence for this specific SNP is
therefore inconsistent and should be considered emerging at best.
In a Mexican seroepidemiological study77 seroepidemiological study
Vargas-Alarcón G et al. Helicobacter
pylori infection and DNMT3a polymorphism are associated with premature coronary
artery disease and subclinical atherosclerosis. Microbiol Pathog, 2022
of 561 premature coronary artery disease patients and 599 controls, individuals
carrying the GG genotype together with H. pylori infection showed a significant
interaction on subclinical atherosclerosis risk (p interaction=1.1×10⁻⁵). This
gene-environment interaction suggests the G allele may alter methylation of
inflammation-related genes in the context of chronic bacterial infection.
A neurological study in Machado-Joseph disease88 Machado-Joseph disease
Ding D et al. Polymorphisms
in DNA methylation-related genes are linked to the phenotype of Machado-Joseph
disease. Neurobiol Aging, 2019
found rs13420827 associated with earlier age-of-onset (p=0.019) in 613 patients
with this CAG-repeat expansion disorder. DNMT3A influences CAG repeat stability
through methylation of repeat-flanking sequences, so a variant affecting DNMT3A
expression may shift the threshold for repeat expansion.
Practical Actions
The actionable implications of rs13420827 center on the same methyl-donor pathway that governs all DNMT3A function. Because DNMT3A uses SAM as its methyl-group donor, ensuring adequate folate and B12 intake is particularly relevant — especially given the ovarian cancer study's finding that the G allele's effect was specifically modified by multivitamin use. G allele carriers should prioritize active, pre-methylated forms of these vitamins to maximize methyl-donor availability without relying on enzymatic conversion steps that may themselves be polymorphic (e.g., MTHFR C677T).
The H. pylori interaction found in the cardiovascular study also suggests that CG and GG carriers may benefit from monitoring for and treating H. pylori infection, given the interaction with DNMT3A methylation capacity on atherosclerosis risk.
Interactions
The most relevant interaction is with MTHFR C677T (rs1801133). MTHFR supplies 5-methyltetrahydrofolate for homocysteine remethylation to methionine, the direct precursor of SAM. Individuals carrying both reduced-function MTHFR and the G allele at rs13420827 face a dual constraint: reduced SAM supply plus possibly altered DNMT3A expression. The companion DNMT3A variant rs11683424 (an intronic variant with stress-response and immune associations) sits in the same gene and may compound any functional shift in DNMT3A activity.
The Kelemen 2008 study explicitly framed rs13420827 within the one-carbon transfer pathway, alongside MTHFR, MTRR (rs1801394), and SLC19A1 (rs1051266), highlighting that this variant's risk modification is pathway-contextual: its effects depend on how well the rest of the folate-methionine cycle is functioning.
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Common homozygote — standard DNMT3A 3' UTR and baseline methylation output
You carry two copies of the common C allele at rs13420827. This is the most frequent genotype, present in approximately 63% of the global population and about 66% of Europeans. The available evidence does not indicate elevated risk from this genotype; in fact, several studies found no significant protective or risk associations for CC individuals at this position relative to the general population. Your DNMT3A methylation output is at the population baseline.
Heterozygous G carrier — possible modest shift in DNMT3A expression
3' UTR variants can alter microRNA binding sites or RNA-binding protein affinity, subtly shifting the amount of DNMT3A protein produced per cell. For CG individuals, the effect is intermediate — one C allele and one G allele contribute to the total DNMT3A output. The methylation-dependent interaction with folate/B-vitamin status is especially relevant here: ensuring methyl-donor substrate is abundant may compensate for any minor expression shift the G allele imparts. Additionally, the cardiovascular interaction with H. pylori (significant in the GG genotype study) may have an attenuated version in heterozygotes, making H. pylori status worth monitoring.
Homozygous G — potential shift in DNMT3A expression with folate-dependent effects
The GG genotype at a 3' UTR regulatory position means both alleles carry the G variant, maximizing whatever expression-level shift this position confers. Two independent lines of evidence suggest GG individuals may experience altered DNMT3A activity: (1) the folate-interaction effect on ovarian cancer risk and (2) the H. pylori-interaction effect on cardiovascular disease. Both are gene-environment interactions, which is typical of regulatory variants with modest main effects — the variant matters most when the environment is suboptimal (low folate, chronic infection). Supporting the methylation substrate pool and eliminating modifiable co-exposures are the primary levers. The neurological data (age-of-onset in Machado-Joseph disease, p=0.019) adds a third convergent line of evidence that DNMT3A expression level is relevant to repeat instability — though this is an emerging finding in a specialized population.